Tumor Lysis Syndrome
Laboratory tumor lysis syndrome (2 or more of the following occurring from 3 days prior up to 7 days after commencement of cytotoxic therapy) Uric acid ≥8 mg/dL or 25…
Transfusion Support
Clinical status Description Hemoglobin level for transfusion (g/dL) Level of evidencea Stable Asymptomatic, imminent marrow recovery <7 1C Vital sign changes Tachycardia, tachypnea, hypotension <8 1C Thrombocytopenia Recent or active…
Diagnostic Approach to White Coat Effect and White Coat Hypertension
Fig. 2.1 Original finger blood pressure and heart rate tracing showing the pressor and tachycardic effects of the physician’s visit in a representative subject. The segment of blood pressure and…
White Coat Hypertension, Metabolic Risk Factors and Cardiovascular Risk Profile
Fig. 6.1 Body mass index, serum total cholesterol, serum triglycerides and serum HDL cholesterol in true normotensive (N), white coat hypertensive (WCH) and true hypertensive (H) subjects of the PAMELA…
White Coat Hypertension: To Treat or Not to Treat
Fig. 8.1 Office systolic blood pressure (SBP), diastolic (D) BP, and heart rate (HR) values at baseline and during antihypertensive drug treatment (1–48 months) in subjects with white coat hypertension…
White Coat Hypertension: Definition, Terminology and Prevalence
Fig. 1.1 Original intra-arterial blood pressure recording performed in a patient before, during, and after a 15 min visit by a physician unknown to the patient. Arrows indicate the beginning…
White Coat Hypertension and Target Organ Damage
Fig. 5.1 Manifestations of subclinical cardiac organ damage related to hypertension: the association between left ventricular hypertrophy (LVH, upper panel) and diastolic dysfunction (lower panel) Several methods characterized by different…
White Coat Hypertension and Cardiovascular Morbidity and Mortality
Fig. 7.1 Cardiovascular (CV) morbid and fatal events in normotension, white coat hypertension, and true hypertension with effective or noneffective (dippers and non-dippers) blood pressure reductions at night (From Verdecchia…
Neurogenic and Non-neurogenic Mechanisms of White-Coat Hypertension
Fig. 3.1 Plots showing mean arterial pressure (MAP), heart rate (HR) and muscle sympathetic nerve activity (MSNA) in normotensive (NT), moderate hypertensive (MH), and severe essential hypertensive (EH) subjects. Data…
Predictive Factors for White-Coat Hypertension
Fig. 4.1 Timing of the maximal increase in both systolic and diastolic finger blood pressure during the physician’s visit. Vertical bars indicate number of subjects showing a maximal blood pressure…
